{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:44:12Z","timestamp":1793317452172,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant osteolysis is a process whereby cancer cells in concert with osteoclasts erode bone matrix. Aminobisphosphonates (NBPs) such as zoledronate induce osteoclast apoptosis and thereby decrease malignant skeletal destruction, severity of bone pain, and frequency of pathologic fracture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>IV-administered zoledronate will reduce homeostatic bone turnover in healthy dogs and pathologic bone resorption in dogs diagnosed with primary and secondary bone tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Six healthy dogs and 20 dogs with naturally occurring primary or metastatic bone tumors were administered zoledronate IV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective study: In all dogs, healthy (n = 6) and with malignant osteolysis (n = 20), the bone biologic effects of zoledronate were evaluated by quantifying changes in serum C-telopeptide (CTx) or urine N-telopeptide (NTx) concentrations or both. In dogs with osteosarcoma (OSA) (n = 10), serial changes in tumor relative bone mineral density (rBMD) assessed by dual-energy x-ray absorptiometry were used to characterize zoledronate's antiresorptive effects within the immediate tumor microenvironment. Additionally, the biochemical tolerability of zoledronate was assessed in 9 dogs receiving multiple (\u22652) consecutive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All dogs had significant reductions in serum CTx or urine NTx concentrations or both after zoledronate administration. In a subset of dogs with appendicular OSA, reduced urine NTx concentrations and increased primary tumor rBMD coincided with improved limb usage as reported by pet owners in dogs treated with zoledronate and concurrent oral analgesics. Multiple zoledronate infusions were not associated with biochemical evidence of toxicosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>In dogs with skeletal neoplasms, IV-administered zoledronate exerts bone biologic effects, appears safe, and can provide pain relief.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2008.0046.x","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:46:10Z","timestamp":1229010370000},"page":"380-387","source":"Crossref","is-referenced-by-count":52,"title":["The Bone Biologic Effects of Zoledronate in Healthy Dogs and Dogs with Malignant Osteolysis"],"prefix":"10.1093","volume":"22","author":[{"given":"T.M.","family":"Fan","sequence":"first","affiliation":[{"name":"University of Illinois at Urbana-Champaign Department of Veterinary Clinical Medicine, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.P.","family":"De Lorimier","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Department of Veterinary Clinical Medicine, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.D.","family":"Garrett","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Department of Veterinary Clinical Medicine, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.I.","family":"Lacoste","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Department of Veterinary Clinical Medicine, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"2026020304194277000_b1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cncr.11144","article-title":"Bone cancer pain","volume":"97","author":"Clohisy","year":"2003","journal-title":"Cancer"},{"key":"2026020304194277000_b2","first-page":"24","article-title":"Clinical usefulness of bisphosphonates in oncology","volume":"22","author":"Veri","year":"2007","journal-title":"Treatment of bone metastases, antitumoral activity and effect on bone resorption markers"},{"key":"2026020304194277000_b3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020304194277000_b4","first-page":"38","article-title":"Toward new horizons","volume":"9","author":"Lipton","year":"2004","journal-title":"The future of bisphosphonate therapy"},{"key":"2026020304194277000_b5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/14712598.5.6.817","article-title":"New therapeutic agents for the treatment of bone diseases","volume":"5","author":"Lipton","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"2026020304194277000_b6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/erc.1.01094","article-title":"Emerging anti-cancer molecular mechanisms of aminobisphosphonates","volume":"13","author":"Caraglia","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"2026020304194277000_b7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2460\/ajvr.2005.66.885","article-title":"Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs","volume":"66","author":"Ashton","year":"2005","journal-title":"Am J Vet Res"},{"key":"2026020304194277000_b8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1290\/1543-706X(2004)040<0113:TEOTBA>2.0.CO;2","article-title":"The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro","volume":"40","author":"Farese","year":"2004","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"2026020304194277000_b9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1476-5810.2003.00026.x","article-title":"The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro","volume":"1","author":"Poirier","year":"2003","journal-title":"Vet Comp Oncology"},{"key":"2026020304194277000_b10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clamp","year":"2004","journal-title":"Lancet Oncol"},{"key":"2026020304194277000_b11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2026020304194277000_b12","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026020304194277000_b13","first-page":"1457","article-title":"Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid","volume":"25","author":"Pectasides","year":"2005","journal-title":"Anticancer Res"},{"issue":"2","key":"2026020304194277000_b14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","article-title":"Anti-tumour activity of zoledronic acid","volume":"31","author":"Clezardin","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"2026020304194277000_b15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1939-1676.2005.tb02661.x","article-title":"Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement","volume":"19","author":"Fan","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020304194277000_b16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1939-1676.2007.tb02986.x","article-title":"Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain","volume":"21","author":"Fan","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020304194277000_b17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1939-1676.2006.tb02865.x","article-title":"Urine N-telopeptide excretion in dogs with appendicular osteosarcoma","volume":"20","author":"Lacoste","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020304194277000_b18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1939-1676.2005.tb02790.x","article-title":"Bone metabolic effects of single-dose zoledronate in healthy dogs","volume":"19","author":"De Lorimier","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020304194277000_b19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/rvsc.2000.0397","article-title":"Urinary markers of type I collagen degradation in the dog","volume":"69","author":"Allen","year":"2000","journal-title":"Res Vet Sci"},{"key":"2026020304194277000_b20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00223-001-1026-x","article-title":"Biological variability in serum and urinary indices of bone formation and resorption in dogs","volume":"70","author":"Ladlow","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2026020304194277000_b21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"2026020304194277000_b22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2026020304194277000_b23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"2026020304194277000_b24","first-page":"1194","article-title":"Zoledronic acid and renal toxicity","volume":"39","author":"Munier","year":"2005","journal-title":"Data from French adverse effect reporting database"},{"key":"2026020304194277000_b25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020304194277000_b26","first-page":"524","article-title":"Impact of zoledronic acid on renal function in patients with cancer","volume":"4","author":"McDermott","year":"2006","journal-title":"Clinical significance and development of a predictive model"},{"key":"2026020304194277000_b27","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026020304194277000_b28","first-page":"19","article-title":"Zoledronic acid to prevent skeletal complications in cancer","volume":"31","author":"Smith","year":"2005","journal-title":"Corroborating the evidence"},{"key":"2026020304194277000_b29","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma","volume":"7","author":"Rosen","year":"2001","journal-title":"A phase III, double-blind, comparative trial"},{"key":"2026020304194277000_b30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/jcb.20589","article-title":"Advances in understanding bone cancer pain","volume":"96","author":"Goblirsch","year":"2005","journal-title":"J Cell Biochem"},{"key":"2026020304194277000_b31","first-page":"4038","article-title":"Osteoprotegerin diminishes advanced bone cancer pain","volume":"61","author":"Luger","year":"2001","journal-title":"Cancer Res"},{"key":"2026020304194277000_b32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpeds.2004.06.066","article-title":"Short-term safety assessment in the use of intravenous zoledronic acid in children","volume":"145","author":"Hogler","year":"2004","journal-title":"J Pediatr"},{"key":"2026020304194277000_b33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/jjco\/hyi005","article-title":"A multicenter and open label clinical trial of zoledronic acid 4\u2003mg in patients with hypercalcemia of malignancy","volume":"35","author":"Kawada","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"2026020304194277000_b34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00130404-200207000-00012","article-title":"Electrolyte abnormalities with zoledronic acid therapy","volume":"8","author":"Sorscher","year":"2002","journal-title":"Cancer J"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2008.0046.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/2\/380\/66674347\/j.1939-1676.2008.0046.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/2\/380\/66674347\/j.1939-1676.2008.0046.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:19:53Z","timestamp":1770110393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/22\/2\/380\/8450052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0046.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,3]]},"published":{"date-parts":[[2008,3,1]]}}}